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Abstract. Human breast cancer displays nuclear accumulation
of ß-catenin and induction of cyclin D1 expression, which
suggests that canonical Wnt/ß-catenin signaling is activated.
In other cancers, the activation of canonical wnt/ß-catenin
signaling is associated with APC, CTNNB1 or AXIN1
mutations. However, these mutations are rare or absent in
breast cancer. In search of alternative mechanisms, we perf-
ormed comprehensive expression analysis of Wnt signaling
molecules, including 19 Wnt ligands, ten Frizzled receptors,
two co-receptors and four Lef/TCF transcription factors in
immortalized normal human mammary epithelial cells (HMEC)
and six breast cancer cell lines. HMEC expressed all Frizzled
receptors except FZD9 and FZD10. They also expressed LRP5
and LRP6 co-receptors, as well as four Lef/TCF transcription
factors. HMEC cells also expressed many Wnt ligands,
including WNT1, WNT2B, WNT3, WNT5A, WNT5B, WNT7B,
WNT9A, WNT10B and WNT16. Redundant expression of
Wnt ligands, Frizzled receptors, co-receptors and Lef/TCF
transcription factors was maintained in breast cancer cell
lines with some exceptions. The most important changes in
cancer cell lines concerned Wnt ligand expression. We noticed
that most breast cancer cell lines overexpressed WNT3A,
WNT4, WNT6, WNT8B, WNT9A and WNT10B. In contrast,
the expression of WNT5A, WNT5B and WNT16 was usually
down-regulated. It is noteworthy that all six Wnt ligands that
are overexpressed in malignant cell lines are known to signal
through the canonical Wnt/ß-catenin signaling pathway,
whereas down-regulated WNT5A and WNT5B ligands
signal via the non-canonical pathway. The expression of both
canonical Wnt ligands and most Frizzled receptors in breast
cancer cell lines suggests that canonical Wnt/ß-catenin
signaling is activated in these cell lines by an autocrine/
paracrine mechanism. In support of this prediction, we
observed nuclear ß-catenin accumulation and cyclin D1
induction in breast cancer cell lines, but not in HMEC. These
results imply that ligand-dependent canonical Wnt/ß-catenin
signaling is active in human breast cancer.
Introduction
Wnt signaling, initially identified in the early embryogenesis
of Drosophila, is involved in a large set of cellular processes,
including proliferation, differentiation, migration, and apoptosis
(1,2). It includes three different pathways; namely the canonical
Wnt/ß-catenin pathway, and non-canonical Wnt/Ca++ and
Wnt/planar cell polarity pathways (3-5). Canonical Wnt
signaling is involved in cell fate choices and stem-cell renewal
and differentiation, whereas non-canonical signaling deals
with morphological changes and tissue organization (3,5,6).
Aberrant activation of the Wnt/ß-catenin signaling pathway
is one of the most frequent abnormalities in human cancer.
In colorectal cancer, canonical Wnt signaling is aberrantly
activated by mutations affecting either the APC tumor
suppressor gene (85%) or ß-catenin-encoding CTNNB1
oncogene (10%) (6). In liver cancer, frequent accumulation
of ß-catenin protein correlated with CTNNB1 and AXIN1
mutations (6), and p53 mutations (7).
Since the discovery of Wnt-1 as a mouse mammary tumor
virus-induced oncogene in mouse breast tumors, Wnt signaling
has become a center of interest in human breast carcinogenesis.
Surprisingly, however, human breast cancers do not display
genetic alterations in the known mutational target genes of
Wnt signaling, including APC, CTNNB1 and AXIN1 (6,8-11).
On the other hand, cyclin D1, a well-known transcriptional
target of canonical Wnt signaling is overexpressed in primary
breast tumors (12). In the absence of related mutations, the
molecular mechanisms of aberrant ß-catenin and cyclin D1
expression in human breast cancer remains poorly known.
In this report, we undertook a systematic study of the
expression of all major components of Wnt signaling in human
breast cancer cell lines. Using the RT-PCR technique, we
analyzed the expression profiles of 19 known Wnt ligands,
10 known Frizzled receptors, two LRP co-receptors and four
Lef/TCF transcription factor genes, in a panel of six breast
cancer cell lines. Telomerase-immortalized normal human
mammary epithelial cell line, hTERT-HME1 (HMEC), was
used as normal control. We also analyzed nuclear ß-catenin
protein, and cyclin D1 and c-myc transcripts in these cells.
Here, we provide evidence that normal and malignant breast
epithelial cells display redundant expression of ligands,
receptors, co-receptors and transcription factors involved in
both canonical and non-canonical Wnt signaling. Our results
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indicate that the expression of canonical Wnt ligands was
up-regulated, whereas non-canonical WNT5A and WNT5B
expression was down-regulated in breast cancer cell lines.
These changes in Wnt ligand expression were correlated with
the accumulation of nuclear ß-catenin and induction of cyclin
D1 expression in breast cancer cell lines, strongly suggesting
that human breast malignancy is associated with ligand-
dependent activation of the canonical Wnt/ß-catenin signaling.
Materials and methods
Cell lines. Breast cancer cell lines (MCF-7, T47-D, BT-474,
BT-20, MDA-MB-453, MDA-MB-468; all from ATCC),
telomerase-immortalized human mammalian epithelial cell
line hTERT-HME1 (HMEC; Clontech) and hepatocellular
carcinoma cell lines, Hep40 and SNU182 (13), were used in
this study. With the exception of HMEC, all cell lines were
grown in Dulbecco's modified Eagle's medium (DMEM)
supplemented with 10% FCS and 50 mg/ml penicillin-
streptomycin. hTERT-HME1 (HMEC) cells were cultivated
in DMEM/Ham's F12 (Biochrom) containing insulin (3.5 μg/
ml), EGF (0.1 ng/ml), hydrocortisone (0.5 μg/ml), 10% FBS
(Biochrom), and 50 mg/ml penicillin-streptomycin.
RNA extraction and cDNA synthesis. Total RNAs were
isolated from cultured cells using the NucleoSpin RNA II Kit
(MN Macherey-Nagel, Duren, Germany) according to the
manufacturer's protocol. The cDNAs were synthesized from
2 μg of total RNA as a template, using RevertAid First Strand
cDNA synthesis kit (MBI Fermentas, Vilnius, Lithuania). A
negative control without reverse transcriptase (1 μl ddH2O
instead) was also prepared for each sample.
RT-PCR and multiplex RT-PCR. The list of primers used for
these analyses is provided in Table I. The PCR reactions were
usually carried out with 1 μl cDNA, using the appropriate
number of cycles and annealing temperature (Tm) provided
in Table I. Negative controls without reverse transcriptase
were included for each set of primers. Multiplex RT-PCR
reactions were carried out using 8 pmol/μl of cyclin D1 or c-
myc primers along with 2 pmol/μl of GAPDH primers for a
total cycle number of 30 and 35 for cyclin D1 and c-myc,
respectively. PCR products were analyzed on a 2% (w/v)
agarose gel prepared with Tris/Acetic acid/EDTA (TAE)
buffer and stained with 5 μg/ml ethidium bromide and
visualized under UV transillumination.
Nuclear extract preparation. For nuclear extraction, cells
were harvested with a scraper in cold PBS, washed twice in
the same buffer and resuspended in 5 volumes of fresh cold
solution A (10 mM HEPES; pH 7.9, 10 mM KCl, 1.5 mM
MgCl2, 0.1 mM EGTA, 0.5 mM DTT and 0.5 mM PMSF).
Resuspended cells were left on ice for 10 min and then
centrifuged at 2000 rpm for 10 min at 4˚C. The pellet was
resuspended in 2 volumes of solution A, and transferred to
a Dounce homogenizer. Twenty strokes were applied with
pestle B. Then, 0.1 volume of restoring solution (1 ml 10X
solution A and 9 ml of 75% sucrose) was added and 4 more
strokes were applied. The nuclear pellet was recovered by
centrifugation at 10000 rpm for 30 sec at 4˚C. The supernatant
(cytosolic fraction) was removed and the nuclear pellet was
resuspended in 1 volume of nuclear resuspension buffer (9 ml
solution A and 1 ml restoring solution) and centrifuged at
10000 rpm for 30 sec. The supernatant was removed and
the nuclear pellet volume (NPV) was measured. The nuclear
pellet was resupended in 5 NPV of solution B (10 mM
HEPES pH 7.9, 400 mM NaCl, 1.5 mM MgCl2, 0.1 mM
EGTA, 0.5 mM DTT, 0.5 mM PMSF and 5% glycerol) and
homogenized by applying 5 strokes with pestle B. The homo-
genate was transferred to a 15-ml snug cap white test tube,
shacked on ice for 30 min, then centrifuged at 13000 rpm for
30 min at 4˚C to remove nuclear membranes. The supernatant
containing the nuclear extract was used for Western blotting.
Western blotting. Nuclear protein extracts from cell lines
were used for Western blot analysis. Antibody to ß-catenin
(Abcam, UK) was obtained commercially, and used as
described previously (13). Equal protein loading was verified
by Coumassie blue staining of the polyacrylamide gel.
Results
The implications of Wnt signaling in breast carcinogenesis
are quite puzzling. On one hand, there is ample evidence for
a direct role of aberrant Wnt signaling in mouse breast carcino-
genesis. On the other hand, human breast cancer does not
display mutations on APC, CTNNB1 and AXIN1 genes that
are known to be frequent mutational targets in other human
cancers. In order to know whether and how the Wnt pathway
genes play a role in human breast cancers, we performed a
comprehensive analysis of major components of the Wnt
signaling pathways in normal and malignant breast cell lines.
Telomerase-immortalized human mammary epithelial cell
line hTERT-HME1 (HMEC) was used as normal control.
We also used a panel of six breast cancer cell lines that are
commonly used for studies related to human breast cancer
biology and genetics (12,14-16).
Redundant expression of Frizzled receptors, LRP co-receptors
and Lef/TCF transcription factors in human breast cancer
cells. In mammals, Wnt signaling is mediated by ten different
Frizzled (FZD) receptors. In addition, LRP5 and LRP6 co-
receptors are involved in the canonical wnt/ß-catenin signaling
pathway. We first analyzed the expression of these receptors
in normal and breast cancer cell lines by RT-PCR. Different
Frizzled receptors have been implicated in canonical and non-
canonical Wnt signaling. Most Frizzled genes lack intronic
sequences. Therefore, we used primers derived from single
exons for these studies. In order to avoid false positives due to
genomic DNA interference, we included reverse transcriptase-
negative controls for all studies. This allowed us to demonstrate
the specificity of our RT-PCR experiments for gene expression.
However, some non-specific bands were unavoidable for
FZD1, FZD4, FZD5, FZD7 and FZD8 in some cell lines. For
these cases, we compared the differences in PCR band
intensities. With these precautions in mind, we detected
strong expression of canonical receptors, FZD1, FZD7, FZD8
(17,18), and non-canonical receptors, FZD3, FZD4, FZD6
(18-20), in HMEC cells. The non-canonical receptors, FZD2
(18) and FZD5 (18,21), were weakly expressed. In contrast,
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we were not able to detect the expression of FZD9 and FZD10
in HMEC cells (Fig. 1). In breast cancer cell lines, the overall
expression pattern of Frizzled receptors did not show any
striking change. The receptors, FZD1, FZD2, FZD4 and
FZD6, were equally well expressed in all six breast cancer
cell lines. Strong expression of FZD3, FZD5, FZD7, FZD8
and FZD9 genes was observed in a subset of these malignant
cell lines. We were unable to detect FZD10 in breast cancer
cell lines, as was the case with HMEC. The LRP5 and LRP6
co-receptors involved in the canonical Wnt signaling pathway
were also expressed in all cell lines (Fig. 1).
Transcriptional regulation by canonical Wnt signaling is
mediated by ß-catenin, which forms active complexes with
the family of four Lef/TCF transcription factors (1,2). Our
results showed strong expression of TCF1 (TCF7), and
moderate expression of LEF1, TCF3 (TCF7L1) and TCF4
(TCF7L2) in HMEC cells. Redundant expression of TCF1,
TCF3 and TCF4 was observed in most of the cancer cell
lines that were tested. The LEF1 gene, on the other hand,
displayed strong expression in only three of the six cell lines
(Fig. 1).
Collectively, these observations indicated that both normal
and malignant breast epithelial cells express all major cell
surface and intracellular components of the Wnt signaling
pathway.
Redundant expression of canonical Wnt ligands in breast
cancer cells. Experimental data from different animal models
indicate that the Wnt pathway generates different signals
mediated by so-called canonical and non-canonical signaling
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Table I. List of primers.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Genes Primer sequence (forward - reverse) Mg Tm Cycle Size (bp)
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
WNT1 CAGTGGAAGGTGCAGTTGCAGC CAGTGGAAGGTGCAGTTGCAGC 2 57 35 469
WNT2 CGGGAATCTGCCTTTGTTTA TCCTTTCCTTTCCTTTCCTT 1.5 57 30 227
WNT2B AAGATGGTGCCAACTTCACC ATTTCTGCATTCCTTGCACC 1.5 55 35 281
WNT3 TCGGCGTGTTAGTGTCCAGG CTTGTGCCAAAGGAACCCGTC 1.5 60 35 396
WNT3A GCACCACCGTCCACGACAGC CCTCGCTACAGCCACCCCAC 1.5 57 35 210
WNT4 CCTTCGTGTACGCCATCTCT TCAGAGCATCCTGACCACTG 1 52 35 142
WNT5A TGGCTTTGGCCATATTTTTC CCGATGTACTGCATGTGGTC 2 55 35 199
WNT5B ACGCATCTGTCTTTGGGAGA CCCTGCTCCTCTGATCCTTT 1 50 35 283
WNT6 GGTTATGGACCCTACCAGCA GGTTATGGACCCTACCAGCA 1.5 58 35 250
WNT7A CCCACCTTCCTGAAGATCAA ACAGCACATGAGGTCACAGC 1.5 57 30 183
WNT7B ATGCACAGAAACTTTCGCAA TGCATCCGGTCCTCTAGAAC 1.5 55 35 590
WNT8A AACCTGTTTATGCTCTGGGC GAAGAGCATTTTCAGGGCAG 2 57 35 205
WNT8B TTCCAAGCAGTTTGTCGATG- GAGATGGAGCGAAAGGTGTC 1.5 57 35 300
WNT9A TGGAGGCCGTGAGCATGAGT CTTAAGGTTGTCTCCGCAGC 1 58 35 272
WNT9B TGCACCTGTGATGACTCTCC CTGATACGCCATGGCACTTA 1 53 35 223
WNT10A TCTTCCTACTGCTGCTGGCT TAGGGGATCTTGTTGCGAGT 1 53 35 274
WNT10B CATCCAGGCACGAATGCCAATC AGGCTCCAGAATTGCGGTTGTG 2 60 35 217
WNT11 GTGTGCTATGGCATCAAGTG AGCTCAATGGAGGAGCAGTT 1 53 35 227
WNT16 CCAAGGAAACTGGATGTGGT TCATGCAGTTCCATCTCTCG 3 54 35 200
FZD1 TCAACTACCACTTCCTGGGG CAGCACAGCACTGACCAAAT 2 52 35 136
FZD2 CTTCTGGGCCACACGAACCAG GGCACCCGGCTGCAGTCCCGG 1.5 55 35 350
FZD3 GTATGGAATATGGACGTGTCACAC TATGAGATCCTTGTGTCACTGTGG 2.5 55 35 581
FZD4 GCCAATGTGCACAGAGAAGA GGTTTTGTGAGGTAAGGGCA 1.5 52 35 211
FZD5 TTCTGGATAGGCCTGTGGTC AGGTAGCAGGCTGACAGGAA 2 52 35 128
FZD6 CAAATTCATGTGGTTCCACCT TGCCTTGGACACCAAAATCCA 1.5 52 35 229
FZD7 CCAACGGCCTGATGTACTTT GAGAACGGTAAAGAGCGTCG 2 50 35 104
FZD8 AAGACAGGCCAGATCGCTAA GACACGAAGAGGTAGCAGGC 2 55 35 215
FZD9 TGCCCCTCTCTGGCTACCTG GGGCACCGTGTAGAGGATGG 1.5 50 35 164
FZD10 CCTCCAAGACTCTGCAGTCC CTCCAAGACTCTGCAGTCC 1.5 50 35 160
LRP5 AAACAGCAGTGCGACTCCTTC TGGCACACAAAATAGACACCA 2 55 35 170
LRP6 TCAAGCACCAAAGGCACTTAC CTTGGCTGTTGCCACTGA 2 52 35 242
LEF1 TCAGGTACAGGTCCAAGAATGA AAGAGGGGTTGGCAGTGATT 1.5 55 35 245
TCF1 TGGCTTCTACTCCCTGACCT TCTCTGCCTTCCACTCTGCT 1.5 57 35 206
TCF3 TCGAGAAGAACAGGCCAAGT GGGGCAGGCTGAACACATTA 1.5 55 35 218
TCF4 TGTACCCAATCACGACAGGA GCCAGCTCGTAGTATTTCGC 1.5 60 35 406
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
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systems. Although the exact mechanisms that differentiate
between these signaling pathways are not well defined, Wnt
ligands appear to play a major role in defining the cellular
choices between canonical and non-canonical pathways,
probably by interacting with selective subsets of Frizzled
receptors (17-23). Therefore, we next compared the expression
pattern of all Wnt ligands in HMEC with that of breast cancer
cell lines. Normal HMEC cells expressed WNT1, WNT2B,
WNT3, WNT5A, WNT5B, WNT7B and WNT16 strongly. They
also expressed WNT9A and WNT10B weakly. The expression
of WNT10A was scarce. On the other hand, HMEC cells
did not express WNT2, WNT3A, WNT4, WNT6, WNT7A,
WNT8A, WNT8B, WNT9B or WNT11, significantly (Fig. 2).
When compared with HMEC, the expression of WNT4,
WNT9A and WNT10B was strongly up-regulated in all
cancer cell lines tested. WN8B expression was also up-
regulated in all cell lines. In addition, the expression of
WNT3A and WNT6 was also up-regulated, but in a subset of
cell lines. In contrast, the expression of WNT5A, WNT5B and
WNT16 was either decreased or lost in breast cancer cell
lines. There was no major change in the expression of other
Wnt ligands, including WNT1, WNT2, WNT3, WNT7A,
WNT8A, WNT9B, WNT10A and WNT11 (Fig. 2).
Table II highlights major Wnt expression changes in
breast cancer cell lines, in comparison with HMEC cells.
Wnt genes whose expression was either up-regulated or
maintained in breast cancer cell lines (WNT3A, WNT4,
WNT6, WNT7B, WNT8B, WNT9A, WNT10B) form group I
ligands. Among these ligands, WNT8B, WNT3A, WNT6,
WNT9A and WNT10B activate only canonical wnt/ß-catenin
signaling. The remaining two (WNT4 and WNT7B) are
known to activate both canonical and non-canonical Wnt
signaling, depending on the cellular context. Furthermore,
WNT4, WNT7B, WNT8B and WNT10B are known to display
transforming activity in mammary epithelial cells in vivo or
in vitro (see Table II for references). Three Wnt ligands,
namely WNT5A, WNT5B and WNT16 form group II ligands
that display down-regulation of expression in most or all
breast cancer cell lines. It is noteworthy that two of these
three ligands, WNT5A and WNT5B, are known to activate
non-canonical wnt signaling, WNT16 being ill-known.
Furthermore, WNT5A has been defined as a tumor suppressor
in other malignancies (24,25) as well as an inhibitor of
canonical Wnt/ß-catenin signaling (24-28). Collectively, these
observations indicate that Wnt ligand expression in human
breast cancer cell lines is dominated by canonical Wnt ligands.
The alteration within the types of Wnt ligand expression
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Figure 1. Expression profile analysis of Frizzled receptors, co-receptors and
Lef/TCF transcription factors in immortalized mammary epithelial (HMEC)
and breast cancer cell lines. Total RNA from each cell line was reverse
transcribed and amplified with primers specific for each indicated gene. PCR
conditions and cycle number were indicated in Table I. PCR products were
resolved on a 2% agarose gel and visualized by ethidium bromide staining.
For all cell lines, RT negative control without reverse transcriptase (-) was
used in parallel with cDNA (+). GAPDH is used as an internal control for
equal cDNA amount. RT, reverse transcriptase.
Figure 2. Expression profile analysis Wnt ligands in immortalized mammary
epithelial (HMEC) and breast cancer cell lines. Total RNA from each cell
line was reverse transcribed and amplified with specific primers for each
indicated Wnt gene. PCR conditions and cycle number were indicated in
Table I. PCR products were resolved on a 2% agarose gel and visualized by
ethidium bromide staining. For all cell lines, RT negative control without
reverse transcriptase (-) was used in parallel with cDNA (+). GAPDH is
used as an internal control for equal cDNA amount. RT, reverse transcriptase.
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strongly suggests a ligand-dependent activation of canonical
wnt/ß-catenin signaling in human breast cancer.
Up-regulation of canonical Wnt ligands in breast cancer cells
correlates with nuclear ß-catenin accumulation and cyclin D1
up-regulation. Nuclear accumulation of ß-catenin has been
reported to be a good indication for canonical Wnt signaling
activity (1,2). Therefore, we next characterized the status of
ß-catenin protein and two major targets of the canonical Wnt
signaling in breast cancer cell lines in comparison with HMEC
cells. As shown in Fig. 3, no nuclear ß-catenin was detected in
HMEC cells. In contrast, all breast cancer cell lines displayed
nuclear accumulation of ß-catenin, which suggests canonical
Wnt signaling activation. This pathway, when activated, leads
to the up-regulation of cyclin D1 and c-myc transcripts in
colorectal cancer (29,30). Therefore, we also analyzed the
transcript levels of these two target genes, using RT-PCR. Our
results showed that the expression of cyclin D1 was weak in
HMEC but was up-regulated in all tested breast cancer cell
lines. We observed a correlation between the up-regulation of
cyclin D1 and nuclear accumulation status of ß-catenin,
although cyclin D1 induction was not proportionally related
to nuclear ß-catenin levels. In contrast to cyclin D1, c-myc
transcript levels were high in HMEC and did not correlate
with nuclear ß-catenin accumulation.
Discussion
Our studies provide several new findings on the role of the
Wnt pathway in human breast cancer cells. Firstly, a large set
of ligands, receptors and transcription factors of the Wnt
signaling pathway is expressed in human mammary epithelial
cells. This strongly suggests that both canonical and non-
canonical Wnt signaling pathways operate in adult mammary
epithelial cells. Secondly, malignant transformation of breast
epithelial cells in humans is associated with subtle changes in
the expression profiles of Wnt signaling components. The
most striking change is the up-regulation of the canonical
Wnt ligands together with a decrease in non-canonical Wnt
ligands. A previously published report indicated the expression
of WNT3, WNT4 and WNT7B, but not WNT3A and WNT7A
in human breast cancer cell lines (14). Our study not only
confirmed these observations but also provided evidence that
WNT9A, WNT10B and WNT8B were also up-regulated in all
breast cancer cell lines studied. Previous reports indicating
WNT8B as a target of estrogen signaling in MCF-7 cells (31),
and WNT10B as a known breast oncogene (32) and its role in
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Table II. Up-regulation of canonical Wnt and down-regulation of non-canonical Wnt ligands in breast cancer cell lines.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Expression in breast Transforming activity
–––––––––––––––––




WNT4 Strongly up-regulated No Yes Canonical and non-canonical (22,23,35-37)
WNT9A Strongly up-regulated ND No data Canonical (38)
WNT10B Strongly up-regulated ND Oncogene Canonical (33,34,39,40)
WNT8B Up-regulated Yes No data Canonical (39)
WNT3A Partially up-regulated Yes No data Canonical (23,39)
WNT6 Partially up-regulated Yes/no No data Canonical (22,23,41)
WNT7B Maintained Yes/no No Canonical and non-canonical (22,23,35,39,42,43)
Group II:
down-regulated
WNT5A Decreased No No data Non-canonical (21-23,25,27,28,44)
WNT5B Decreased/lost Yes/no No Non-canonical (22,23,44,45)
WNT16 Lost ND No data No data (46)
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Figure 3. Nuclear accumulation of ß-catenin protein and induction of cyclin
D1 transcripts in breast cancer cell lines. Nuclear protein fractions from
HMEC and breast cancer cell lines were subjected to 10% PAGE and
probed with a monoclonal anti-ß-catenin antibody. Loading control was
made by Coumassie blue staining of total nuclear proteins. Middle and
bottom panel shows multiplex RT-PCR analysis of cyclin D1 or c-myc
together with GAPDH as an internal control.
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the development of mammary adenocarcinomas in mice (33)
increase the importance of our results. Other Wnt ligands,
WNT6, WNT7A and WNT10A, were also overexpressed, but
only in a few breast cancer cell lines. It is noteworthy that all
Wnt ligands that are expressed or overexpressed in breast
cancer cell lines are able to trigger canonical Wnt signaling
(see Table II and references therein). Several other Wnt ligands,
including WNT5A, WNT5B and WNT16, were expressed in
HMEC but down-regulated in breast cancer cell lines. WNT5A
and WNT5B are known to signal for the non-canonical
pathway (see Table II and references therein). It therefore
appears that, despite the redundant expression of many Wnt
ligands in both non-malignant and malignant breast epithelial
cell lines, breast cancer malignancy is associated with an
overall up-regulation of canonical Wnt/ß-catenin signaling.
Canonical Wnt/ß-catenin signaling plays a major role in
cytoplasmic and/or nuclear accumulation of ß-catenin
(2,5,6,12,34). Accumulation of ß-catenin protein with
induction of cyclin D1 expression is known to be a marker
of poor prognosis in breast cancer (12). In line with these
observations, we provide evidence for the nuclear accumul-
ation of ß-catenin in breast cancer cell lines. In contrast, HMEC
did not display any nuclear accumulation. It is known that
breast cancer cells do not display mutations in known genes
of the canonical Wnt-ß-catenin signaling (6,8-11). Therefore,
nuclear ß-catenin expression in breast cancer cells probably
results from the autocrine activation of canonical signaling
through the help of Wnt ligands that we have shown to be
overexpressed in malignant cells. As shown in Fig. 3, there
are differential nuclear ß-catenin levels amongst the breast
cancer cell lines that we tested. This difference may be an
indication that the autocrine Wnt signaling in these cells occurs
at variable intensities due to the heterogeneous expression of
canonical and non-canonical Wnt ligands. An autocrine Wnt
signaling mechanism has recently been proposed for breast
cancer (15) and our results support this contention. We also
noticed that, nuclear ß-catenin accumulation shows a moderate
correlation with cyclin D1 transcript levels in HMEC and breast
cancer cell lines, whereas c-myc, another known target of
canonical wnt-ß-catenin signaling, appears to act independently
(Fig. 3).
In conclusion, we propose that redundant expression of
several canonical Wnt ligands is involved in the activation of
canonical wnt/ß-catenin signaling, nuclear accumulation of
ß-catenin and induction of cyclin D1 overexpression in human
breast cancer cell lines. This ligand-dependent and probably
autocrine mechanism may provide an explanation for the lack
of mutations in genes located downstream of Wnt-mediated
Frizzled activation in human mammary cancer, despite the
demonstrated role of Wnt genes in mouse breast cancer. Wnt
ligands and Frizzled receptors that are overexpressed in breast
cancer cells may serve as critical targets for the development
of novel target-driven therapeutic applications for mammary
tumors.
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